The SBI Healthcare Opportunities Fund delivered a 18.2% return over the past three months, outperforming major competitors in the sector. Investors often look at consistent performance across longer periods to assess mutual fund strength. While short-term gains can be significant, the fund's ability to beat its benchmark over three years highlights its active management strategy.
Detailed Coverage
The SBI Healthcare Opportunities Fund has emerged as the top performer within the pharmaceutical and healthcare mutual fund category, according to data available as of July 21, 2026. The fund recorded an 18.2% return over the three-month period, establishing a lead over other prominent schemes in the sector. This ranking considered funds with at least Rs 1,500 crore in assets under management to ensure the comparison reflects established investment vehicles.
Comparison with Sector Peers
When evaluated against competitors, the fund's recent performance remains notable. The DSP Healthcare Fund and Mirae Asset Healthcare Fund recorded returns of 17.2% and 15.1% respectively during the same three-month window. While these funds also showed strong performance, the SBI scheme maintained its lead in both the six-month and one-year categories, delivering a 26.5% and 16.1% return respectively. Investors should note that the Nippon India Pharma Fund currently manages the largest corpus among these top five funds, with assets totaling Rs 9,044.2 crore.
Long-Term Performance and Benchmarks
Beyond short-term returns, the fund has demonstrated consistent results against its benchmark index. On a one-year basis, the fund's 16.1% return significantly exceeded the benchmark's 4.4% return. This gap of 11.8 percentage points reflects the fund's active investment decisions within the healthcare industry. Over a three-year period, the fund also outperformed its benchmark, generating returns that stayed ahead of the index by 6.6 percentage points, with the benchmark yielding 16.8% over the same duration.
Understanding Sector Dynamics
While the SBI Healthcare Opportunities Fund leads in recent performance, other funds like the ICICI Prudential Pharma Healthcare & Diagnostics Fund have shown strength over longer durations, leading the category with a 24.6% return on a three-year basis. Because the pharmaceutical sector can be sensitive to regulatory changes, drug pricing policies, and global export demand, returns in these funds can fluctuate based on broader market conditions. For investors, evaluating a fund's performance across multiple cycles is important, as market leadership can shift based on specific drug approvals, generic demand, or domestic pricing environment trends. Tracking how a fund manages volatility compared to its peers remains a key practice for those invested in thematic healthcare funds.